

Pavel Katsel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1473747/publications.pdf>

Version: 2024-02-01

41
papers

3,136
citations

186265

28
h-index

302126

39
g-index

45
all docs

45
docs citations

45
times ranked

4974
citing authors

#	ARTICLE	IF	CITATIONS
1	Engagement of vascular early response genes typifies mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2022, 18, 1357-1369.	0.8	5
2	FSH blockade improves cognition in mice with Alzheimer's disease. <i>Nature</i> , 2022, 603, 470-476.	27.8	131
3	Molecular signature of extracellular matrix pathology in schizophrenia. <i>European Journal of Neuroscience</i> , 2021, 53, 3960-3987.	2.6	42
4	Transformative Network Modeling of Multi-omics Data Reveals Detailed Circuits, Key Regulators, and Potential Therapeutics for Alzheimer's Disease. <i>Neuron</i> , 2021, 109, 257-272.e14.	8.1	108
5	Molecular subtyping of Alzheimer's disease using RNA sequencing data reveals novel mechanisms and targets. <i>Science Advances</i> , 2021, 7, .	10.3	137
6	Multiscale causal networks identify VGF as a key regulator of Alzheimer's disease. <i>Nature Communications</i> , 2020, 11, 3942.	12.8	94
7	Comparison of brain connectomes by MRI and genomics and its implication in Alzheimer's disease. <i>BMC Medicine</i> , 2020, 18, 23.	5.5	6
8	The expression of long noncoding RNA NEAT1 is reduced in schizophrenia and modulates oligodendrocytes transcription. <i>NPJ Schizophrenia</i> , 2019, 5, 3.	3.6	44
9	CDT2-controlled cell cycle reentry regulates the pathogenesis of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 217-231.	0.8	28
10	Is Alzheimer disease a failure of mobilizing immune defense? Lessons from cognitively fit oldest-old. <i>Dialogues in Clinical Neuroscience</i> , 2019, 21, 7-19.	3.7	6
11	Moderate decline in select synaptic markers in the prefrontal cortex (BA9) of patients with Alzheimer's disease at various cognitive stages. <i>Scientific Reports</i> , 2018, 8, 938.	3.3	51
12	Overexpression of Truncated Human DISC1 Induces Appearance of Hindbrain Oligodendroglia in the Forebrain During Development. <i>Schizophrenia Bulletin</i> , 2018, 44, 515-524.	4.3	3
13	The Mount Sinai cohort of large-scale genomic, transcriptomic and proteomic data in Alzheimer's disease. <i>Scientific Data</i> , 2018, 5, 180185.	5.3	320
14	Microvascular anomaly conditions in psychiatric disease. <i>Schizophrenia - angiogenesis connection</i> . <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 77, 327-339.	6.1	58
15	[P2-107]: COMBINATION THERAPY OF TYPE 2 DIABETES MEDICATIONS AS A TREATMENT TARGET FOR ALZHEIMER DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P648.	0.8	1
16	Multiscale network modeling of oligodendrocytes reveals molecular components of myelin dysregulation in Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2017, 12, 82.	10.8	100
17	S4-0203: Accelerating Medicines Partnership: Co-Expression Networks. <i>Alzheimer's and Dementia</i> , 2016, 12, P322.	0.8	0
18	Integrative network analysis of nineteen brain regions identifies molecular signatures and networks underlying selective regional vulnerability to Alzheimer's disease. <i>Genome Medicine</i> , 2016, 8, 104.	8.2	224

#	ARTICLE	IF	CITATIONS
19	Impaired mitochondrial energy metabolism as a novel risk factor for selective onset and progression of dementia in oldest-old subjects. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 565.	2.2	13
20	The triggering receptor expressed on myeloid cells 2 (<i>TREM2</i>) is associated with enhanced inflammation, neuropathological lesions and increased risk for Alzheimer's dementia. <i>Alzheimer's and Dementia</i> , 2015, 11, 1163-1170.	0.8	70
21	Non-viability of crossing the Alzheimer mouse model Tg2576 with the type 2 diabetes mouse model <i>ob/ob</i> . <i>Neurobiology of Aging</i> , 2014, 35, e19-e20.	3.1	13
22	O3-04-03: CROSS-TISSUE METHYLOMIC PROFILING IN ALZHEIMER'S DISEASE. , 2014, 10, P215-P215.		0
23	Cycle Checkpoint Abnormalities during Dementia: A Plausible Association with the Loss of Protection against Oxidative Stress in Alzheimer's Disease. <i>PLoS ONE</i> , 2013, 8, e68361.	2.5	46
24	Molecular and Genetic Evidence for Abnormalities in the Nodes of Ranvier in Schizophrenia. <i>Archives of General Psychiatry</i> , 2012, 69, 7.	12.3	97
25	A System-Level Transcriptomic Analysis of Schizophrenia Using Postmortem Brain Tissue Samples. <i>Archives of General Psychiatry</i> , 2012, 69, 1205.	12.3	94
26	Association of ApoE and LRP mRNA levels with dementia and AD neuropathology. <i>Neurobiology of Aging</i> , 2012, 33, 628.e1-628.e14.	3.1	32
27	Synaptic protein deficits are associated with dementia irrespective of extreme old age. <i>Neurobiology of Aging</i> , 2012, 33, 1125.e1-1125.e8.	3.1	26
28	Expression of mutant human DISC1 in mice supports abnormalities in differentiation of oligodendrocytes. <i>Schizophrenia Research</i> , 2011, 130, 238-249.	2.0	37
29	Astrocyte and Glutamate Markers in the Superficial, Deep, and White Matter Layers of the Anterior Cingulate Gyrus in Schizophrenia. <i>Neuropsychopharmacology</i> , 2011, 36, 1171-1177.	5.4	79
30	Microarray Database Mining and Cell Differentiation Defects in Schizophrenia. <i>Advances in Experimental Medicine and Biology</i> , 2011, 696, 67-74.	1.6	7
31	Increased expression of cholesterol transporter ABCA1 is highly correlated with severity of dementia in AD hippocampus. <i>Brain Research</i> , 2010, 1318, 167-177.	2.2	46
32	Increased expression of RXR α in dementia: an early harbinger for the cholesterol dyshomeostasis?. <i>Molecular Neurodegeneration</i> , 2010, 5, 36.	10.8	29
33	Gene expression abnormalities and oligodendrocyte deficits in the internal capsule in schizophrenia. <i>Schizophrenia Research</i> , 2010, 120, 150-158.	2.0	64
34	PGC-1 α Expression Decreases in the Alzheimer Disease Brain as a Function of Dementia. <i>Archives of Neurology</i> , 2009, 66, 352-61.	4.5	323
35	Transcriptional vulnerability of brain regions in Alzheimer's disease and dementia. <i>Neurobiology of Aging</i> , 2009, 30, 561-573.	3.1	77
36	Gain in Brain Immunity in the Oldest-Old Differentiates Cognitively Normal from Demented Individuals. <i>PLoS ONE</i> , 2009, 4, e7642.	2.5	50

#	ARTICLE	IF	CITATIONS
37	Abnormal Indices of Cell Cycle Activity in Schizophrenia and their Potential Association with Oligodendrocytes. <i>Neuropsychopharmacology</i> , 2008, 33, 2993-3009.	5.4	90
38	Variations in oligodendrocyte-related gene expression across multiple cortical regions: implications for the pathophysiology of schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2007, 10, 565.	2.1	89
39	Gene Expression Alterations in the Sphingolipid Metabolism Pathways during Progression of Dementia and Alzheimer's Disease: A Shift Toward Ceramide Accumulation at the Earliest Recognizable Stages of Alzheimer's Disease?. <i>Neurochemical Research</i> , 2007, 32, 845-856.	3.3	213
40	The Human Homolog of the QKI Gene Affected in the Severe Dysmyelination "Quaking" Mouse Phenotype: Downregulated in Multiple Brain Regions in Schizophrenia. <i>American Journal of Psychiatry</i> , 2006, 163, 1834-1837.	7.2	78
41	Variations in myelin and oligodendrocyte-related gene expression across multiple brain regions in schizophrenia: A gene ontology study. <i>Schizophrenia Research</i> , 2005, 79, 157-173.	2.0	204